Viking Historical Financial Ratios
| VKTX Stock | USD 54.51 1.09 2.04% |
Viking Therapeutics is promptly reporting on over 104 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0, PTB Ratio of 5.29 or Days Sales Outstanding of 0.0 will help investors to properly organize and evaluate Viking Therapeutics financial condition quickly.
Viking |
About Viking Financial Ratios Analysis
Viking TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Viking Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Viking financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Viking Therapeutics history.
Viking Therapeutics Financial Ratios Chart
Add Fundamental
Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Payables Turnover
A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.Most ratios from Viking Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Viking Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Viking Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Viking Stock please use our How to Invest in Viking Therapeutics guide.At this time, Viking Therapeutics' Graham Net Net is fairly stable compared to the past year. Price Book Value Ratio is likely to rise to 5.29 in 2024, whereas Free Cash Flow Yield is likely to drop (0.04) in 2024.
Viking Therapeutics fundamentals Correlations
Click cells to compare fundamentals
Viking Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Viking Therapeutics fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Ptb Ratio | 2.08 | 1.67 | 1.76 | 4.97 | 5.04 | 5.29 | |
| Book Value Per Share | 3.85 | 3.37 | 2.62 | 1.89 | 3.69 | 3.88 | |
| Free Cash Flow Yield | (0.0429) | (0.0533) | (0.13) | (0.067) | (0.0418) | (0.0439) | |
| Operating Cash Flow Per Share | (0.34) | (0.3) | (0.62) | (0.63) | (0.78) | (0.82) | |
| Pb Ratio | 2.08 | 1.67 | 1.76 | 4.97 | 5.04 | 5.29 | |
| Free Cash Flow Per Share | (0.34) | (0.3) | (0.62) | (0.63) | (0.78) | (0.82) | |
| Roic | (0.15) | (0.16) | (0.27) | (0.47) | (0.29) | (0.3) | |
| Net Income Per Share | (0.36) | (0.5) | (0.7) | (0.88) | (0.91) | (0.96) | |
| Cash Per Share | 3.83 | 3.42 | 2.62 | 2.02 | 3.84 | 4.03 | |
| Pocfratio | (23.32) | (18.77) | (7.46) | (14.92) | (23.93) | (25.13) | |
| Interest Coverage | (223.88) | (402.47) | (3.1K) | (1.1K) | (1.3K) | (1.3K) | |
| Pfcf Ratio | (23.32) | (18.77) | (7.46) | (14.92) | (23.93) | (25.13) | |
| Income Quality | 0.85 | 0.96 | 0.55 | 0.87 | 0.7 | 0.51 | |
| Roe | (0.093) | (0.15) | (0.27) | (0.46) | (0.25) | (0.26) | |
| Ev To Operating Cash Flow | (23.0) | (17.45) | (6.91) | (14.2) | (23.19) | (24.35) | |
| Pe Ratio | (22.39) | (11.34) | (6.58) | (10.72) | (20.44) | (21.46) | |
| Return On Tangible Assets | (0.0907) | (0.14) | (0.26) | (0.4) | (0.23) | (0.24) | |
| Ev To Free Cash Flow | (23.0) | (17.45) | (6.91) | (14.2) | (23.19) | (24.35) | |
| Earnings Yield | (0.0447) | (0.0882) | (0.15) | (0.0933) | (0.0489) | (0.0514) | |
| Net Debt To E B I T D A | 0.3 | 0.67 | 0.48 | 0.5 | 0.54 | 0.57 | |
| Current Ratio | 41.83 | 21.12 | 23.98 | 7.61 | 19.19 | 14.1 | |
| Tangible Book Value Per Share | 3.85 | 3.37 | 2.62 | 1.89 | 3.69 | 3.88 | |
| Graham Number | 5.57 | 6.13 | 6.42 | 6.11 | 8.7 | 9.43 | |
| Shareholders Equity Per Share | 3.85 | 3.37 | 2.62 | 1.89 | 3.69 | 3.88 | |
| Graham Net Net | 3.73 | 3.25 | 2.5 | 1.72 | 3.63 | 3.81 | |
| Interest Debt Per Share | 0.006226 | 0.006006 | 6.09E-4 | 0.003957 | 0.004367 | 0.004149 | |
| Enterprise Value Over E B I T D A | (22.44) | (8.91) | (5.94) | (9.77) | (16.88) | (16.03) | |
| Price Earnings Ratio | (22.39) | (11.34) | (6.58) | (10.72) | (20.44) | (21.46) | |
| Price Book Value Ratio | 2.08 | 1.67 | 1.76 | 4.97 | 5.04 | 5.29 | |
| Price Earnings To Growth Ratio | 4.25 | (0.29) | (0.16) | (0.42) | (6.0) | (5.7) | |
| Price To Operating Cash Flows Ratio | (23.32) | (18.77) | (7.46) | (14.92) | (23.93) | (25.13) | |
| Price To Free Cash Flows Ratio | (23.32) | (18.77) | (7.46) | (14.92) | (23.93) | (25.13) | |
| Effective Tax Rate | (0.27) | 0.0872 | 0.018 | 0.0216 | 0.0194 | 0.0204 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Viking Stock Analysis
When running Viking Therapeutics' price analysis, check to measure Viking Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viking Therapeutics is operating at the current time. Most of Viking Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viking Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viking Therapeutics' price. Additionally, you may evaluate how the addition of Viking Therapeutics to your portfolios can decrease your overall portfolio volatility.